Impact of epidermal growth factor receptor expression on disease-free survival and rate of pelvic relapse in patients with advanced cancer of the cervix treated with chemoradiotherapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 4, 2011, Pages 395-400

  Pérez Regadera, José ^a   Sánchez Muñoz, Alfonso ^b   De La Cruz, Javier ^a   Ballestín, Claudio ^a   Lora, David ^a   García Martín, Rosa ^a   Sotoca, Amalia ^a   Pérez Ruiz, Elisabeth ^b   Lanzós, Eduardo ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

advanced cancer of the cervix; epidermal growth factor receptor (EGFR)

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; TEGAFUR;

ADVANCED CANCER; ARTICLE; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; EPIDERMOID TUMOR; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; RECURRENCE RISK; TUMOR VOLUME; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PELVIC NEOPLASMS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 79961171714     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181e84634     Document Type: Article

References (38)

1. Pisan P, Parkin DM, Bray F, et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83:18-29. (Pubitemid 29409471)
2. Waggoner SE. Cervical cancer. Lancet. 2003;361:2217-2225. (Pubitemid 36782559)
3. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high risk cervical cancer: An update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22:872-880. (Pubitemid 41103599)
4. Rose P, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Eng J Med. 1999;349:1144-1151.
5. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxiurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol. 1999;17:1339-1348. (Pubitemid 29220838)
6. Keys HM, Bundy BN, Stheman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant histerectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154-1160.
7. Peters WA III, Liu PY, Barret RJ II, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high risk early stage carcinoma of the cervix. J Clin Oncol. 2000;18:1606-1613. (Pubitemid 30220538)
8. Thomas GM. Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy. N Engl J Med. 1999;340:1198-1199.
9. Pearcey R, Brundage M, Drouin P, et al. Phase III trial comparing concurrent radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002;20:966-972. (Pubitemid 34141839)
10. Benda JA. Histopathologic prognostic factors in early stage cervical carcinoma. Monogr Natl Cancer Inst. 1996;21:27-34.
11. Tanaka Y, Sawada S, Murata T, et al. Relationship between lymph node metastases and prognosis in patients irradiated postoperatively for carcinoma of the uterine cervix. Acta Radiol. 1984;23:455-459. (Pubitemid 15073560)
12. Delgado G, Bundy B, Zaino R, et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecol Oncol. 1990;38: 352-357. (Pubitemid 20362555)
13. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-137. (Pubitemid 33674041)
14. Arteaga CL. Epidermal growth factor dependence in human tumors: More than just expression? The Oncologist. 2002;7(suppl 4):31-39. (Pubitemid 34977161)
15. Salomon DS, Bradt R, Ciardello F, et al. Epidermal growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183-232.
16. Pfeiffer D, Stellwag B, Pfeiffer A, et al. Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 1989;33:146-150. (Pubitemid 19112903)
17. Hale RJ, Buckley CH, Gullick WJ, et al. Prognostic value of epidermal growth factor receptor in cervical carcinoma. J Clin Pathol. 1993;46:149-153. (Pubitemid 23076346)
18. Kristensen GB, Holm R, Abeler VM, et al. Evaluation of the prognosis significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. Cancer. 1996;78:433-440. (Pubitemid 26250528)
19. Kersermaekers AF, Fleuren GJ, Kenter GG, et al. Oncogene alterations in carcinomas of the uterine cervix: Overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res. 1999;5: 577-586. (Pubitemid 29131967)
20. Kim YT, Park SW, Kim JW. Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gynecol Oncol. 2002;87: 84-89. (Pubitemid 36027106)
21. Gaffney DK, Haslam D, Tsodikov A, et al. Epidermal growth factor and vascular endothelial growth factor negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;4:922-928. (Pubitemid 36794022)
22. Lee CM, Lee RJ, Hammond E, et al. Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: Prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis. Gynecol Oncol. 2004;93:209-214. (Pubitemid 38429572)
23. Hayashi Y, Hachisuga T, Iwasaka T, et al. Expression of ras oncogen product and EGF receptor in cervical squamous cell carcinomas and its relationship to lymph node involvement. Gynecol Oncol. 1991;40:147-150.
24. Oka K, Nakano T, Arai T. Expression of cathepsin D and epidermal growth factor in stage III cervical carcinomas. Int J Gynecol Cancer. 1997;7:122-126. (Pubitemid 27237399)
25. Scambia G, Ferrandina G, Distefano M, et al. Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer. Cancer Lett. 1998;123:135-139. (Pubitemid 28064090)
26. Ngan H, Cheung A, Cheng D, et al. Abnormal expression of the epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: Correlation with human papillomavirus and prognosis. Tumor Biol. 2001;22: 176-183. (Pubitemid 32245414)
27. Hove MG, Dinh TV, Hannigan EV, et al. Oncogene expression and microvessel count in recurrent and nonrecurrent stage Ib squamous cell carcinoma of the cervix. J Reprod Med. 1999;44:493-496. (Pubitemid 29293473)
28. Nagai N, Oshita T, Fujii T, et al. Prospective analysis of DNA ploidy, proliferative index and epidermal growth factor receptor as prognostic factors for pretreated uterine cancer. Oncol Rep. 2000;7:551-559.
29. National Cancer Institute. NCI Clinical Announcement. Bethesda, MD: United States Department of Health and Human Services, Public Health Service, National Institute of Health; 1999.
30. Sheridan MT, ODwyer T, Seymour CB, et al. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig. 1997;5:180-186. (Pubitemid 27426395)
31. Akimoto T, Hunter NC, Buchmiller L, et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res. 1999;5:2884-2890. (Pubitemid 29493967)
32. Giralt J, de las Heras M, Cerezo L, et al. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: A multicenter, retrospective analysis. Radiother Oncol. 2005;74:101-108. (Pubitemid 40331866)
33. Kim JW, Kim YT, Kim DK, et al. Expression of epidermal growth factor receptor in carcinoma of the cervix. Gynecol Oncol. 1996;60:283-287. (Pubitemid 26058774)
34. Bolli JA, Maners A. Age as a prognostic factor in cancer of the cervix: The UAMS experience. J Ark Med Soc. 1992;89:79-83.
35. Borowsky MA, Elliott KS, Pezzullo JC, et al. A retrospective review of 15 years of radical radiotherapy with or without concurrent cisplatin and/or 5-fluorouracil for the treatment of locally advanced cervical cancer. Bull Cancer. 2005;92:19-24.
36. Fyles AW, Pintilie M, Kirkbride P, et al. Prognostic factors in patients with cervix cancer treated by radiation therapy: Results of a multiple regression analysis. Radiother Oncol. 1995;35:107-117.
37. Ling YH, Donato NJ, Perez-Soler R. Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines. Cancer Chemother Pharmacol. 2001;47:473-480. (Pubitemid 32477293)
38. Knecht R, Peters S, Adunka O, et al. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents. Anticancer Res. 2003;23(3B):2577-2583. (Pubitemid 36903186)